Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.70 |
| ▸ | CA2 | P00918 | 5/20 | 0.70 |
| ▸ | ACHE | P22303 | 5/20 | 0.70 |
| ▸ | DRD3 | P35462 | 6/20 | 0.57 |
| ▸ | DRD2 | P14416 | 5/20 | 0.57 |
| ▸ | DRD4 | P21917 | 4/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4782371 | 0.87 | CA1 (0.52) | CA1CA2ACHEDRD3DRD2 | |
| SCHEMBL9669811 | 0.86 | CA1 (0.72) | CA1CA2ACHEDRD3DRD2 | |
| SCHEMBL7450053 | 0.83 | HDAC8 (0.52) | CA1CA2ACHEDRD3DRD2 | |
| SCHEMBL7450046 | 0.83 | HDAC8 (0.52) | CA1CA2ACHEDRD3DRD2 | |
| SCHEMBL5722246 | 0.80 | CA1 (0.64) | CA1CA2ACHEDRD3DRD2 | |
| SCHEMBL9136687 | 0.80 | CA1 (0.64) | CA1CA2ACHEDRD3DRD2 | |
| SCHEMBL5677299 | 0.80 | CA1 (0.64) | CA1CA2ACHEDRD3DRD2 | |
| SCHEMBL9851515 | 0.80 | MTNR1A (0.73) | CA1CA2MTNR1AMTNR1BGRIN2B | |
| SCHEMBL30612411 | 0.80 | MTNR1A (0.73) | CA1CA2MTNR1AMTNR1BGRIN2B | |
| SCHEMBL9443695 | 0.80 | CA1 (0.57) | CA1CA2ACHEDRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2012012322-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| EP-1957460-A1 | BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007067444-A1 | BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | CA1 725/4885CA2 810/4885ACHE 1462/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | CA1 4184/4885CA2 1767/4885ACHE 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.